-
Quoin Pharmaceuticals NasdaqCM:QNRX Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Location: 42127 Pleasant Forest Court, Ashburn, VA, 20148-7349, United States | Website: https://quoinpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
177.9M
Cash
11.55M
Avg Qtr Burn
-2.254M
Short % of Float
1.25%
Insider Ownership
7.08%
Institutional Own.
7.20%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
QRX003 Details Netherton syndrome | Phase 3 Initiation | |
QRX003 Details Pediatric Netherton Syndrome (NS) | Phase 1/2 Data readout | |
QRX003 Details Pediatric Peeling skin syndrome | Phase 1 Data readout |